Logo

RZLT

Rezolute, Inc.

RZLT

Rezolute, Inc. • NASDAQ
$9.72 ▲ 1.67% (+0.16)
Market Cap $901.31 M
52w High $11.46
52w Low $2.21
Dividend Yield 0%
P/E -10.34
Volume 517.02K
Outstanding Shares 92.73M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 $19.817M ▼ $-18.15M ▲ 0% $-0.18 ▲ $-18.142M ▲
Q4-2025 $0 $25.85M ▲ $-24.39M ▼ 0% $-0.26 ▲ $-25.842M ▼
Q3-2025 $0 $20.023M ▲ $-18.914M ▼ 0% $-0.27 ▼ $-20.016M ▼
Q2-2025 $0 $17.08M ▲ $-15.73M ▼ 0% $-0.22 $-17.072M ▼
Q1-2025 $0 $16.941M $-15.378M 0% $-0.22 $-16.933M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $152.194M ▼ $158.664M ▼ $11.496M ▼ $147.168M ▼
Q4-2025 $167.858M ▲ $175.49M ▲ $13.363M ▲ $162.127M ▲
Q3-2025 $86.892M ▼ $94.739M ▼ $12.17M ▼ $82.569M ▼
Q2-2025 $96.54M ▼ $112.007M ▼ $12.418M ▲ $99.589M ▼
Q1-2025 $108.273M $123.414M $9.973M $113.441M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-18.15M ▲ $-17.43M ▲ $-68.49M ▼ $911K ▼ $-85.009M ▼ $-17.43M ▲
Q4-2025 $-24.39M ▼ $-21.995M ▼ $346K ▼ $101.16M ▲ $79.511M ▲ $-21.995M ▼
Q3-2025 $-18.914M ▼ $-17.4M ▼ $23.054M ▲ $10K ▼ $5.664M ▲ $-17.4M ▼
Q2-2025 $-15.73M ▼ $-13.666M ▲ $11.469M ▲ $657K ▼ $-1.54M ▲ $-13.666M ▲
Q1-2025 $-15.378M $-16.014M $-49.41M $5.5M $-59.924M $-16.014M

Five-Year Company Overview

Income Statement

Income Statement Rezolute is still a pure R&D story with no product sales yet, so its income statement is driven entirely by research and corporate costs. Losses have been consistent over the past several years as the company funds clinical trials, with a gradual step‑up as programs advance into later stages. Per‑share losses have moved around, likely reflecting past share structure changes rather than a big swing in the underlying business. Overall, the pattern is what you’d expect from a clinical‑stage biotech: ongoing, predictable losses with the hope that current spending sets up future revenue if drugs are approved.

Balance Sheet

Balance Sheet The balance sheet is lean but fairly clean. Assets are modest and heavily concentrated in cash, with very little in the way of physical assets or long‑term investments. The company currently carries essentially no financial debt, and equity remains positive, which reduces balance‑sheet risk but also reflects the fact that operations have been financed primarily through issuing shares. The limited size of the asset base highlights that Rezolute needs future access to capital markets, partnerships, or successful commercialization to support its programs over time.

Cash Flow

Cash Flow Cash flows show a classic early‑stage biotech profile: steady cash outflows from operating activities as the company funds trials and overhead, and virtually no spending on large physical assets. Because there is no revenue, all cash burn comes from expenses, and free cash flow is negative but relatively stable. This suggests a controlled burn rate, yet it also underscores dependence on external financing or future milestone payments to keep programs progressing.

Competitive Edge

Competitive Edge Rezolute is trying to build a strong position in narrowly defined, high‑need niches rather than broad, crowded markets. Its lead program, ersodetug, targets hyperinsulinism with a mechanism that differs from existing drugs and surgery, which could be a meaningful advantage if clinical results are strong. Orphan drug status and a streamlined late‑stage trial design add regulatory and time‑to‑market benefits. However, as a small company in a sector that includes much larger pharma players, Rezolute remains vulnerable to competing approaches, clinical setbacks, and the challenge of building commercial infrastructure in rare diseases.

Innovation and R&D

Innovation and R&D Innovation is the core of the Rezolute story. The lead antibody, ersodetug, works by modulating the insulin receptor rather than simply reducing insulin production, potentially allowing treatment across many forms of hyperinsulinism. This is a differentiated scientific angle that, if validated, could be a genuine step forward for patients with few good options. The second asset, an oral drug for diabetic macular edema, aims to replace or supplement frequent eye injections with a pill, which would be a major quality‑of‑life improvement. The company’s R&D strategy is focused, with a small number of high‑impact programs, but success hinges on positive late‑stage trial readouts and smooth execution in complex rare‑disease studies.

Summary

Rezolute is a classic clinical‑stage biotech: no commercial revenue yet, recurring losses, and a balance sheet built mostly on cash raised from investors rather than debt. Financially, it appears disciplined but clearly dependent on continued access to capital until a product is approved. Strategically, the company is concentrated in rare and metabolic diseases where medical need is high and competition is thinner, using a novel mechanism for hyperinsulinism and a more convenient oral approach for an eye disease. The key opportunities lie in upcoming Phase 3 and Phase 2 data, potential regulatory approvals, and the benefits of orphan‑drug positioning. The main risks are typical for this stage: trial failure, delays, competition from alternative treatments, and the ongoing need to fund operations without current product revenue.

NEWS

November 10, 2025 · 5:30 PM UTC

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more

November 6, 2025 · 4:05 PM UTC

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Read more

November 5, 2025 · 7:30 AM UTC

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Read more

October 15, 2025 · 8:00 AM UTC

Rezolute to Participate in Upcoming Investor Conferences

Read more

October 9, 2025 · 4:05 PM UTC

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more